Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels DOI Creative Commons
Coco Dekkers, Nicolaas P. A. Zuithoff, Daphne S. Bakker

и другие.

Allergy, Год журнала: 2024, Номер unknown

Опубликована: Дек. 14, 2024

ABSTRACT Introduction and Objectives Tralokinumab—a biological that specifically targets interleukin‐13—is one of the newer advanced systemic treatments for patients with moderate‐to‐severe atopic dermatitis (AD). Although safety efficacy have been shown in phase‐III clinical trials, daily practice data are needed. Therefore, aim this study was to evaluate 28‐week effectiveness, serum proteins total IgE levels adult AD treated tralokinumab practice. Materials Methods Data all who started treatment participated BioDay registry were collected at baseline, after 4,16 28 weeks treatment. Clinical evaluated by outcome measures, such as Eczema Area Severity Index (EASI) well patient‐reported numerical rating scale (NRS) pruritus. Adverse events evaluated. In a subgroup patients, 18 measured serum. Results A 84 included, whom 39 dupilumab‐naïve (D‐naïve) 45 dupilumab non‐naïve (D‐non‐naïve) patients. All primary outcomes significantly improved during probability achieving EASI ≤ 7 NRS‐pruritis 4 75.8% (56.9–88.2) 51.4% (28.0–74.2), respectively. The disease severity‐associated TARC/CCL17 PARC/CCL18 decreased treatment, D‐naïve most reported adverse eye disorders ( n = 24, 28.6%). 23 (27.4%) discontinued due and/or ineffectiveness, hair loss being common event leading discontinuation 6). Conclusion Tralokinumab is an effective both previously failed on effect supported data.

Язык: Английский

Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis DOI
Amalie Thorsti Møller Rønnstad, Christopher G. Bunick, Raj Chovatiya

и другие.

American Journal of Clinical Dermatology, Год журнала: 2025, Номер unknown

Опубликована: Март 5, 2025

Язык: Английский

Процитировано

1
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series DOI
Niccolò Gori,

Elena Ippoliti,

Silvia Ferrucci

и другие.

Journal of the European Academy of Dermatology and Venereology, Год журнала: 2024, Номер 38(10)

Опубликована: Фев. 29, 2024

Enquiries related to the data generated or analysed during this study can be directed corresponding author.

Язык: Английский

Процитировано

6
Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study DOI Creative Commons
Laura Marina Calabrese, Élisa Cinotti, Martina D’Onghia

и другие.

Acta Dermato Venereologica, Год журнала: 2025, Номер 105, С. adv42275 - adv42275

Опубликована: Март 12, 2025

Tralokinumab is a monoclonal antibody selectively targeting IL-13, approved for moderate-to-severe atopic dermatitis (AD), which real-world data are scarce. This prospective, observational, multicentric study aimed to assess the long-term effectiveness and safety of tralokinumab in patients with AD setting. Primary outcomes included 50%, 75%, 90% improvement Eczema Area Severity Index score (EASI50, EASI75, EASI90, respectively) improvements Dermatology Life Quality (DLQI) at 1 year. A total 136 were enrolled study; 1-year follow-up available 111 patients. After year, 68.5% 33.3% achieved an EASI75 respectively. significantly higher percentage than without foot involvement EASI50 (p = 0.009) 0.022). Similarly, hand was associated response 0.005). Median DLQI decreased from 9.00 (interquartile range (IQR): 6.00, 13.75) 1.00 (IQR: 0.00, 4.00) after year treatment. Adverse events blepharitis (n 10), conjunctivitis 6), injection-site reactions 2). can be effective safe treatment AD. Involvement certain body areas, such as hands feet, might positively predict clinical tralokinumab.

Язык: Английский

Процитировано

0
An Open-Label Prospective Observational Study of Tralokinumab in Atopic Dermatitis Patients with Inadequate Response to Dupilumab DOI
Meredith Tyree Polaskey,

Sheiva Fakhraie,

Karishma Daftary

и другие.

Dermatitis, Год журнала: 2024, Номер unknown

Опубликована: Авг. 1, 2024

Язык: Английский

Процитировано

3
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels DOI Creative Commons
Coco Dekkers, Nicolaas P. A. Zuithoff, Daphne S. Bakker

и другие.

Allergy, Год журнала: 2024, Номер unknown

Опубликована: Дек. 14, 2024

ABSTRACT Introduction and Objectives Tralokinumab—a biological that specifically targets interleukin‐13—is one of the newer advanced systemic treatments for patients with moderate‐to‐severe atopic dermatitis (AD). Although safety efficacy have been shown in phase‐III clinical trials, daily practice data are needed. Therefore, aim this study was to evaluate 28‐week effectiveness, serum proteins total IgE levels adult AD treated tralokinumab practice. Materials Methods Data all who started treatment participated BioDay registry were collected at baseline, after 4,16 28 weeks treatment. Clinical evaluated by outcome measures, such as Eczema Area Severity Index (EASI) well patient‐reported numerical rating scale (NRS) pruritus. Adverse events evaluated. In a subgroup patients, 18 measured serum. Results A 84 included, whom 39 dupilumab‐naïve (D‐naïve) 45 dupilumab non‐naïve (D‐non‐naïve) patients. All primary outcomes significantly improved during probability achieving EASI ≤ 7 NRS‐pruritis 4 75.8% (56.9–88.2) 51.4% (28.0–74.2), respectively. The disease severity‐associated TARC/CCL17 PARC/CCL18 decreased treatment, D‐naïve most reported adverse eye disorders ( n = 24, 28.6%). 23 (27.4%) discontinued due and/or ineffectiveness, hair loss being common event leading discontinuation 6). Conclusion Tralokinumab is an effective both previously failed on effect supported data.

Язык: Английский

Процитировано

0